# Cambridge AI-designed vaccine shows safety in humans > Source: > Published: 2026-06-05 17:55:01.284962+00:00 # Cambridge AI-designed vaccine shows safety in humans A University of Cambridge team and spin-out DIOSynVax reported that a first-in-human trial of an AI-designed "super-antigen" vaccine was safe and immunogenic. Per a University of Cambridge press release and trial reporting, the Phase 1 study enrolled **39 healthy volunteers** between December 2021 and September 2023 and tested a vaccine candidate intended to provide broad protection against **Sarbeco coronaviruses**, including SARS-CoV-2. The studies, published in the Journal of Infection and described in institutional press releases (University of Cambridge; University Hospital Southampton), state that the vaccine, whose active component was "designed entirely by computer simulations," triggered immune responses to SARS-CoV-2, SARS and related bat coronaviruses and produced no significant side-effects in the small cohort. The research teams say a larger Phase 2 study is planned to assess broader immunogenicity and diversity of responses. ### What happened A Cambridge-led team and spin-out **DIOSynVax** trialled an AI-designed vaccine intended to give broad protection across the **Sarbeco coronavirus** group. Per the University of Cambridge press release, the Phase 1 trial enrolled **39 healthy volunteers** at NIHR clinical research facilities in Southampton and Cambridge between December 2021 and September 2023, and the results are published in the **Journal of Infection** (sources: University of Cambridge; UHS; News-Medical). The trial tested a vaccine whose active component is an AI-designed "super-antigen" that, according to the Cambridge materials, was produced by analysing global genetic sequence data and by computer simulation. The institutional reporting states the candidate was administered as a DNA vaccine via a microfluidic jet, a needle-free delivery method, and provoked immune responses to **SARS-CoV-2**, **SARS**, and related bat viruses, with no significant safety signals in this small cohort (sources: cam.ac.uk; UHS press release; Global News). ### Technical details Editorial analysis - technical context: Public reporting describes the active ingredient as a computationally designed antigen that aggregates features common across a virus family, rather than using a single strain-derived protein. The Cambridge release frames this as a way to broaden epitope coverage and reduce the need for frequent reformulation. The trial used a DNA-delivery format in this instance; reporting notes the antigen is compatible with multiple delivery platforms (sources: cam.ac.uk; UHS). ### Context and significance Editorial analysis: The result joins a stream of recent work where machine learning and large-scale sequence analysis accelerate biologics design, similar to applications of structural prediction and generative models in protein engineering. For practitioners, AI-driven antigen design could shorten the antigen selection loop and enable designs that target conserved features across related viruses, but early-phase safety and immunogenicity do not by themselves prove broad, durable protection or manufacturability at scale. ### Limitations reported The published trial is Phase 1 and limited to **39** volunteers, and the institutional accounts state the study demonstrates safety and immunogenicity signals only in that small, healthy adult cohort (sources: cam.ac.uk; News-Medical). Reporting indicates a larger Phase 2 trial is planned to assess immune responses in a wider and more diverse population; detailed neutralization breadth, durability, and correlates of protection are not reported in the press summaries (sources: UHS; Global News). ### What to watch For practitioners: monitor the upcoming Phase 2 protocol and published immunology readouts for quantitative neutralization data across panels of zoonotic and human Sarbeco viruses, assessments of durability of response, T cell profiling, and comparisons across delivery platforms. Observers should also track peer-reviewed publication of full trial datasets, any independent neutralization or challenge-study follow-ups, and regulatory engagement or manufacturing assessments that speak to scalability. ### Bottom line Editorial analysis: The Cambridge/DIOSynVax effort is a notable example of AI applied to antigen design that has reached human testing and produced supportive Phase 1 safety and immunogenicity signals. The result is an early-stage proof point for computational vaccine design, but substantial clinical, immunological, and production evidence will be required before assessing impact on public-health vaccine strategy (sources: University of Cambridge; University Hospital Southampton; Journal of Infection reporting). ## Scoring Rationale This is a notable, early-stage demonstration that AI-designed antigens can reach human testing and produce safety and immunogenicity signals. The result matters to researchers and practitioners working at the intersection of ML and vaccine design, but it remains Phase 1 with limited cohort size and pending broader immunological and manufacturing evidence. Practice interview problems based on real data 1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with. [Try 250 free problems](/problems)